Sueyama H
Department of Radiology, Faculty of Medicine, University of the Ryukyus.
Nihon Gan Chiryo Gakkai Shi. 1990 Aug 20;25(8):1608-18.
Thirteen patients with previously untreated advanced squamous cell carcinoma of the esophagus were treated with pre-radiation chemotherapy followed by radiation therapy. The chemotherapy consisted of two or three cycles of Cisplatin and 120 hour continuous infusion of 5-Fluorouracil. Three patients showed complete response (CR), three partial response (PR), three minor response (MR) and four non-response (NR). The overall response rate was 46%. The predominant side effects were nausea, vomiting and anorexia. Mild or moderate degree of anemia and leukocytopenia were also noticed. However, no serious toxicity was observed. Radiation therapy was administered to eleven of the thirteen patients, excluding one patient who refused it and one patient who died during chemotherapy. In two of the eleven cases, however, radiotherapy was discontinued because of MR, and surgery was performed. In one additional case, post-radiotherapy surgery was performed. One of these three cases received curative esophagectomy. After definitive treatment, CR was obtained in 54% (7 of 13), PR in 15% (2 of 13), MR in 15% and NR in 15%. The non-effective patients (PR + MR + NR) died within nine months after the initiation of treatment. Two of the CR patients later died, one due to local recurrence and another due to aortic-esophageal fistula with no residual cancer discovered at autopsy. The remaining CR patients are still alive and well, after 11.5 to 32 months. Although the follow-up period is yet short, the combination of radiation therapy with pre-radiotherapy chemotherapy appears to be an effective treatment.
13例先前未经治疗的晚期食管鳞状细胞癌患者接受了放疗前化疗,随后进行放射治疗。化疗包括两或三个周期的顺铂以及5-氟尿嘧啶120小时持续输注。3例患者显示完全缓解(CR),3例部分缓解(PR),3例轻度缓解(MR),4例无缓解(NR)。总缓解率为46%。主要副作用为恶心、呕吐和厌食。还注意到轻度或中度贫血和白细胞减少。然而,未观察到严重毒性。13例患者中有11例接受了放射治疗,其中1例拒绝放疗,1例在化疗期间死亡。然而,在这11例中的2例中,由于轻度缓解而停止放疗,并进行了手术。另外1例进行了放疗后手术。这3例中有1例接受了根治性食管切除术。在确定性治疗后,13例中有7例(54%)获得CR,2例(15%)获得PR,15%为MR,15%为NR。无效患者(PR + MR + NR)在治疗开始后9个月内死亡。2例CR患者后来死亡,1例死于局部复发,另1例死于主动脉食管瘘,尸检未发现残留癌。其余CR患者在11.5至32个月后仍然存活且状况良好。尽管随访期尚短,但放疗与放疗前化疗相结合似乎是一种有效的治疗方法。